74.31

7.91% +5.45

After Hours: 74.40 0.09 +0.12%

Viking Therapeutics Inc (VKTX)

Overview News Price History Option Chain Why VKTX Down? Discussions Forecast

Viking Therapeutics Inc stock is currently priced at $74.31, with a 24-hour trading volume of 3.51M. It has seen a +7.91% increased in the last 24 hours and a -8.07% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $66.86 pivot point. If it approaches the $77.78 resistance level, significant changes may occur.

Previous Close:

$68.86

Open:

$69

24h Volume:

3.51M

Market Cap:

$8.19B

Revenue:

Net Income/Loss:

$-93.72M

P/E Ratio:

-79.90

EPS:

-0.93

Net Cash Flow:

$-54.87M

1W Performance:

+17.17%

1M Performance:

-8.07%

6M Performance:

+668.86%

1Y Performance:

+280.10%

1D Range:

$68.22

$74.64

52W Range:

$8.28

$99.41

Viking Therapeutics Inc Stock (VKTX) Company Profile

Name

Viking Therapeutics Inc

Sector

Healthcare (1191)

Industry

Biotechnology (688)

Phone

858-704-4660

Address

12340 El Camino Real, Suite 250, San Diego, CA

Employee

Twitter

@viking_vktx

Next Earnings Date

2024-05-21

Latest SEC Filings

VKTX's Discussions on Twitter

Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-31-23	Resumed	ROTH MKM	Buy
Mar-28-23	Reiterated	Maxim Group	Buy
Mar-17-23	Initiated	Stifel	Buy
Jul-29-21	Resumed	BTIG Research	Buy
May-25-21	Downgrade	Raymond James	Strong Buy → Outperform
Jun-05-20	Initiated	BMO Capital Markets	Outperform
May-05-20	Initiated	Chardan Capital Markets	Buy
May-01-20	Initiated	BTIG Research	Buy
Jul-16-19	Initiated	Oppenheimer	Outperform
Jun-25-19	Initiated	Stifel	Buy
Mar-29-19	Upgrade	SVB Leerink	Mkt Perform → Outperform
Mar-14-19	Reiterated	Maxim Group	Buy
Feb-22-19	Initiated	SVB Leerink	Mkt Perform
Dec-12-18	Initiated	B. Riley FBR	Buy
Nov-19-18	Upgrade	Raymond James	Outperform → Strong Buy
Sep-18-18	Reiterated	H.C. Wainwright	Buy
Sep-18-18	Reiterated	Maxim Group	Buy
Sep-18-18	Reiterated	Raymond James	Outperform
Jul-20-18	Initiated	SunTrust	Buy
Jun-28-18	Initiated	Raymond James	Outperform
Jun-01-18	Reiterated	Laidlaw	Buy
May-31-18	Reiterated	Maxim Group	Buy
Mar-26-18	Resumed	H.C. Wainwright	Buy
Nov-28-17	Reiterated	Maxim Group	Buy
Nov-21-17	Initiated	ROTH Capital	Buy

View All

Viking Therapeutics Inc Stock (VKTX) Latest News

3 Millionaire-Maker Biotech Stocks

The Motley Fool

Viking Therapeutics Reports Q1 Results: 'An Exceptional Period' Says CEO

Benzinga

Missed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon.

The Motley Fool

Viking Therapeutics Inc Stock (VKTX) Financials Data

Viking Therapeutics Inc (VKTX) Net Income 2024

VKTX net income (TTM) was -$93.72 million for the quarter ending March 31, 2024, a -29.64% decrease year-over-year.

Viking Therapeutics Inc (VKTX) Cash Flow 2024

VKTX recorded a free cash flow (TTM) of -$54.87 million for the quarter ending March 31, 2024, a +12.23% increase year-over-year.

Viking Therapeutics Inc (VKTX) Earnings per Share 2024

VKTX earnings per share (TTM) was -$0.93 for the quarter ending March 31, 2024, a +2.11% growth year-over-year.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures. The company is also developing VK2809, an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in a Phase II clinical trial for the treatment of patients with hypercholesterolemia and fatty liver disease; and in a Phase I clinical trial to treat patients who suffer from glycogen storage disease type Ia. In addition, it is developing VK0214 for X-linked adrenoleukodystrophy, which is in pre-clinical stage. Viking Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.